Dopamine transporter availability in medication free and in bupropion treated depression

A 99mTc-TRODAT-1 SPECT study

Miklós Árgyelán, Zoltán Szabó, Balázs Kanyó, Attila Tanács, Zsuzsanna Kovács, Z. Janka, L. Pávics

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Background: Bupropion is thought to exert its antidepressive effect by blocking the dopamine transporter (DAT). The purpose of this study was to evaluate the DAT activity in depressed patients by means of 99mTc- TRODAT-1 SPECT in relation to the efficacy of bupropion treatment. Methods: In 12 healthy controls and 16 depressed patients the baseline DAT activity was examined. Nine of the 16 patients went through an additional second SPECT investigation, after 4 weeks of bupropion treatment. Results: In the depressed patients, the baseline DAT striatum-occipital ratio (SOR) (1.04 ± .36, mean ± SD) was not significantly different from that in the control group (1.12 ± .33) (p > .05). Correlation was found between baseline SOR and HAM-D score change (r = - .745, p = .02) of the bupropion treated patients. The average DAT occupancy due to the bupropion treatment was 20.84 ± 27.7%. No significant correlation between the therapeutical effectiveness and the occupancy was observed. Limitations: One of the limiting factors of our study has been the lack of drug monitoring. Conclusions: In good agreement with other PET studies, we found 20.84% DAT occupancy during bupropion treatment. The lack of correlation between the efficacy of therapy and occupancy of DAT may raise the question as to whether other mechanisms are involved in the effect of bupropion.

Original languageEnglish
Pages (from-to)115-123
Number of pages9
JournalJournal of Affective Disorders
Volume89
Issue number1-3
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Bupropion
Dopamine Plasma Membrane Transport Proteins
Single-Photon Emission-Computed Tomography
Drug Monitoring
Therapeutics
technetium Tc 99m TRODAT-1
Control Groups

Keywords

  • Bupropion
  • DAT
  • Depression
  • Occupancy
  • SPECT
  • TRODAT-1

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Dopamine transporter availability in medication free and in bupropion treated depression : A 99mTc-TRODAT-1 SPECT study. / Árgyelán, Miklós; Szabó, Zoltán; Kanyó, Balázs; Tanács, Attila; Kovács, Zsuzsanna; Janka, Z.; Pávics, L.

In: Journal of Affective Disorders, Vol. 89, No. 1-3, 12.2005, p. 115-123.

Research output: Contribution to journalArticle

Árgyelán, Miklós ; Szabó, Zoltán ; Kanyó, Balázs ; Tanács, Attila ; Kovács, Zsuzsanna ; Janka, Z. ; Pávics, L. / Dopamine transporter availability in medication free and in bupropion treated depression : A 99mTc-TRODAT-1 SPECT study. In: Journal of Affective Disorders. 2005 ; Vol. 89, No. 1-3. pp. 115-123.
@article{115d70b8191944dda3ab21a30997efab,
title = "Dopamine transporter availability in medication free and in bupropion treated depression: A 99mTc-TRODAT-1 SPECT study",
abstract = "Background: Bupropion is thought to exert its antidepressive effect by blocking the dopamine transporter (DAT). The purpose of this study was to evaluate the DAT activity in depressed patients by means of 99mTc- TRODAT-1 SPECT in relation to the efficacy of bupropion treatment. Methods: In 12 healthy controls and 16 depressed patients the baseline DAT activity was examined. Nine of the 16 patients went through an additional second SPECT investigation, after 4 weeks of bupropion treatment. Results: In the depressed patients, the baseline DAT striatum-occipital ratio (SOR) (1.04 ± .36, mean ± SD) was not significantly different from that in the control group (1.12 ± .33) (p > .05). Correlation was found between baseline SOR and HAM-D score change (r = - .745, p = .02) of the bupropion treated patients. The average DAT occupancy due to the bupropion treatment was 20.84 ± 27.7{\%}. No significant correlation between the therapeutical effectiveness and the occupancy was observed. Limitations: One of the limiting factors of our study has been the lack of drug monitoring. Conclusions: In good agreement with other PET studies, we found 20.84{\%} DAT occupancy during bupropion treatment. The lack of correlation between the efficacy of therapy and occupancy of DAT may raise the question as to whether other mechanisms are involved in the effect of bupropion.",
keywords = "Bupropion, DAT, Depression, Occupancy, SPECT, TRODAT-1",
author = "Mikl{\'o}s {\'A}rgyel{\'a}n and Zolt{\'a}n Szab{\'o} and Bal{\'a}zs Kany{\'o} and Attila Tan{\'a}cs and Zsuzsanna Kov{\'a}cs and Z. Janka and L. P{\'a}vics",
year = "2005",
month = "12",
doi = "10.1016/j.jad.2005.08.016",
language = "English",
volume = "89",
pages = "115--123",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Dopamine transporter availability in medication free and in bupropion treated depression

T2 - A 99mTc-TRODAT-1 SPECT study

AU - Árgyelán, Miklós

AU - Szabó, Zoltán

AU - Kanyó, Balázs

AU - Tanács, Attila

AU - Kovács, Zsuzsanna

AU - Janka, Z.

AU - Pávics, L.

PY - 2005/12

Y1 - 2005/12

N2 - Background: Bupropion is thought to exert its antidepressive effect by blocking the dopamine transporter (DAT). The purpose of this study was to evaluate the DAT activity in depressed patients by means of 99mTc- TRODAT-1 SPECT in relation to the efficacy of bupropion treatment. Methods: In 12 healthy controls and 16 depressed patients the baseline DAT activity was examined. Nine of the 16 patients went through an additional second SPECT investigation, after 4 weeks of bupropion treatment. Results: In the depressed patients, the baseline DAT striatum-occipital ratio (SOR) (1.04 ± .36, mean ± SD) was not significantly different from that in the control group (1.12 ± .33) (p > .05). Correlation was found between baseline SOR and HAM-D score change (r = - .745, p = .02) of the bupropion treated patients. The average DAT occupancy due to the bupropion treatment was 20.84 ± 27.7%. No significant correlation between the therapeutical effectiveness and the occupancy was observed. Limitations: One of the limiting factors of our study has been the lack of drug monitoring. Conclusions: In good agreement with other PET studies, we found 20.84% DAT occupancy during bupropion treatment. The lack of correlation between the efficacy of therapy and occupancy of DAT may raise the question as to whether other mechanisms are involved in the effect of bupropion.

AB - Background: Bupropion is thought to exert its antidepressive effect by blocking the dopamine transporter (DAT). The purpose of this study was to evaluate the DAT activity in depressed patients by means of 99mTc- TRODAT-1 SPECT in relation to the efficacy of bupropion treatment. Methods: In 12 healthy controls and 16 depressed patients the baseline DAT activity was examined. Nine of the 16 patients went through an additional second SPECT investigation, after 4 weeks of bupropion treatment. Results: In the depressed patients, the baseline DAT striatum-occipital ratio (SOR) (1.04 ± .36, mean ± SD) was not significantly different from that in the control group (1.12 ± .33) (p > .05). Correlation was found between baseline SOR and HAM-D score change (r = - .745, p = .02) of the bupropion treated patients. The average DAT occupancy due to the bupropion treatment was 20.84 ± 27.7%. No significant correlation between the therapeutical effectiveness and the occupancy was observed. Limitations: One of the limiting factors of our study has been the lack of drug monitoring. Conclusions: In good agreement with other PET studies, we found 20.84% DAT occupancy during bupropion treatment. The lack of correlation between the efficacy of therapy and occupancy of DAT may raise the question as to whether other mechanisms are involved in the effect of bupropion.

KW - Bupropion

KW - DAT

KW - Depression

KW - Occupancy

KW - SPECT

KW - TRODAT-1

UR - http://www.scopus.com/inward/record.url?scp=28444466222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444466222&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2005.08.016

DO - 10.1016/j.jad.2005.08.016

M3 - Article

VL - 89

SP - 115

EP - 123

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 1-3

ER -